Sironax

Series-B+
sironax.com Biotech & Healthcare Waltham, United States 51-100
Total Funding $200M
Latest Round Undisclosed Series-B+
Last Announced Sep 4, 2025
Investors Undisclosed
Decision Makers 5 Verified

About Sironax

Sironax develops therapies for neurodegenerative, inflammatory, immunologic, metabolic, and rare diseases. It conducts clinical studies of SIR2501, SIR4156, and SIR9900. Sironax also develops the Brain Delivery Module platform. Its customers are patients with these diseases.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Waltham, United States
Team Size 51-100
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website sironax.com
Domain Registered Date Jun 5, 2017

Social & Network Presence

X / Twitter Profile @Sironax_Ltd (0 followers) Created on Mar 2025
LinkedIn Corporate Not linked

Company Milestones & Timeline

4 Events
  1. Capital Raise

    Series-B+ announced

    fundraisingfox.com

  2. Milestone

    X account created (@Sironax_Ltd)

    0 followers

  3. Capital Raise

    Raised $200,000,000 · Series-B+

    fundraisingfox.com

  4. Milestone

    Website domain registered

    sironax.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Sironax.

Funding History

2 Rounds
Series-B+ · Sep 4, 2025
Series-B+ · Aug 2, 2022

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts